Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2024 08:17 ET | Source: SciSparc Ltd

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
December 13, 2023 08:18 ET | Source: SciSparc Ltd

SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform

MitoCareX Bio met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
October 03, 2023 07:33 ET | Source: SciSparc Ltd

SciSparc Granted European Patent for its Core Technology

The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
September 07, 2023 09:15 ET | Source: SciSparc Ltd

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
June 30, 2023 09:25 ET | Source: SciSparc Ltd

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 ...
June 21, 2023 09:00 ET | Source: SciSparc Ltd

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
March 09, 2023 07:30 ET | Source: SciSparc Ltd

SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Israeli Ministry of Health granted an approval to use SCI-110 in a clinical trial at the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel TEL AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) --...
March 06, 2023 07:45 ET | Source: SciSparc Ltd

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...